TY - JOUR
T1 - Scalp Invasion by Atypical or Anaplastic Meningioma Is a Risk Factor for Development of Systemic Metastasis
AU - Garzon-Muvdi, Tomas
AU - Maxwell, Russell
AU - Luksik, Andrew
AU - Kessler, Remi
AU - Weingart, Jon
AU - Olivi, Alessandro
AU - Bettegowda, Chetan
AU - Tamargo, Rafael
AU - Brem, Henry
AU - Lim, Michael
N1 - Funding Information:
Conflict of interest statement: Chetan Bettegowda is a consultant for Depuy-Synthes. Henry Brem received research funding from the National Institutes of Health, Arbor Pharmaceuticals, BMS, and Accurexa∗ and philanthropy, Consultant for AsclepiX Therapeutics, Celsion-EGEN, Perosphere Inc., StemGen, Accelerating Combination Therapies∗, Camden Partners, LikeMinds, Inc, Acuity Bio Corp (∗includes equity). Michael Lim received research support from Arbor, Aegenus, Altor, BMS, Immunocellular, Celldex, Accuray and is a consultant for Aegenus, BMS, Regeneron. He is also a nonresearch consultant for Stryker.
Funding Information:
Conflict of interest statement: Chetan Bettegowda is a consultant for Depuy-Synthes. Henry Brem received research funding from the National Institutes of Health, Arbor Pharmaceuticals, BMS, and Accurexa? and philanthropy, Consultant for AsclepiX Therapeutics, Celsion-EGEN, Perosphere Inc., StemGen, Accelerating Combination Therapies?, Camden Partners, LikeMinds, Inc, Acuity Bio Corp (?includes equity). Michael Lim received research support from Arbor, Aegenus, Altor, BMS, Immunocellular, Celldex, Accuray and is a consultant for Aegenus, BMS, Regeneron. He is also a nonresearch consultant for Stryker.
Publisher Copyright:
© 2020
PY - 2020/10
Y1 - 2020/10
N2 - Background: Atypical and anaplastic meningiomas (AAMs) are rare and comprise approximately 5% of all meningiomas. Extracranial metastases in meningioma patients occur in 0.1% of all cases, but these lesions are difficult to treat and may be a poor prognostic factor. Methods: We conducted a retrospective chart review between 1990 and 2016 of patients who had surgical resection of AAM. In a cohort of 149 patients, 6 had metastatic lesions that were histologically confirmed to be meningioma. We compared baseline characteristics between patients with and without metastasis and performed a multivariate Cox regression analysis to assess risk factors for the development of systemic metastasis. Results: Six patients had histologically confirmed meningioma metastasis. We hypothesized that the presence of scalp invasion in patients could be a potential risk factor for the development of systemic meningioma metastasis. Nine out of the 149 patients without metastasis had scalp invasion, whereas 4 out of the 6 patients with metastasis had scalp invasion. Patients with metastasis had a median age of 62 ± 20. Patients without metastasis had a median age of 59 ± 15 years. Gender distribution was similar; approximately 50% of patients in each group were female. Eighty-five percent of patients with metastatic disease were white, and 65% of patients without metastatic disease were white. Among patients without metastatic disease, 77% had World Health Organization II tumors, whereas 50% of patients with metastatic disease had World Health Organization II tumors. In multivariate analysis including age, tumor grade, size, location, extent of resection, sex, and scalp invasion, the only significant predictor of systemic metastasis was scalp invasion (odds ratio = 39.67; 95% confidence interval = 3.74–421.12; P = 0.0023). Median overall survival (OS) with metastasis was 126 months, and median OS without metastasis was 158 months. Having metastatic disease was not significantly associated with worse OS (P = 0.33). Conclusions: Metastasis development from AAM is a rare but serious event. Because scalp invasion is a strongly associated predictive factor for development of systemic metastasis in patients with AAM, it is necessary to consider strategies to prevent and to be vigilant of the development of scalp invasion.
AB - Background: Atypical and anaplastic meningiomas (AAMs) are rare and comprise approximately 5% of all meningiomas. Extracranial metastases in meningioma patients occur in 0.1% of all cases, but these lesions are difficult to treat and may be a poor prognostic factor. Methods: We conducted a retrospective chart review between 1990 and 2016 of patients who had surgical resection of AAM. In a cohort of 149 patients, 6 had metastatic lesions that were histologically confirmed to be meningioma. We compared baseline characteristics between patients with and without metastasis and performed a multivariate Cox regression analysis to assess risk factors for the development of systemic metastasis. Results: Six patients had histologically confirmed meningioma metastasis. We hypothesized that the presence of scalp invasion in patients could be a potential risk factor for the development of systemic meningioma metastasis. Nine out of the 149 patients without metastasis had scalp invasion, whereas 4 out of the 6 patients with metastasis had scalp invasion. Patients with metastasis had a median age of 62 ± 20. Patients without metastasis had a median age of 59 ± 15 years. Gender distribution was similar; approximately 50% of patients in each group were female. Eighty-five percent of patients with metastatic disease were white, and 65% of patients without metastatic disease were white. Among patients without metastatic disease, 77% had World Health Organization II tumors, whereas 50% of patients with metastatic disease had World Health Organization II tumors. In multivariate analysis including age, tumor grade, size, location, extent of resection, sex, and scalp invasion, the only significant predictor of systemic metastasis was scalp invasion (odds ratio = 39.67; 95% confidence interval = 3.74–421.12; P = 0.0023). Median overall survival (OS) with metastasis was 126 months, and median OS without metastasis was 158 months. Having metastatic disease was not significantly associated with worse OS (P = 0.33). Conclusions: Metastasis development from AAM is a rare but serious event. Because scalp invasion is a strongly associated predictive factor for development of systemic metastasis in patients with AAM, it is necessary to consider strategies to prevent and to be vigilant of the development of scalp invasion.
KW - Anaplastic meningioma
KW - Atypical meningioma
KW - Metastasis
KW - Scalp invasion
UR - http://www.scopus.com/inward/record.url?scp=85088393444&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088393444&partnerID=8YFLogxK
U2 - 10.1016/j.wneu.2020.06.148
DO - 10.1016/j.wneu.2020.06.148
M3 - Article
C2 - 32599198
AN - SCOPUS:85088393444
SN - 1878-8750
VL - 142
SP - e133-e139
JO - World Neurosurgery
JF - World Neurosurgery
ER -